TDMS Study 93029-04 Pathology Tables
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
Facility: National Center for Toxicological Research
Chemical CAS #: 129-73-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 48 48 48 48
Early Deaths
Natural Death 7 2 2 5
Moribund 4 5 7 4
Survivors
Terminal Sacrifice 37 41 39 39
Animals Examined Microscopically 47 48 47 47
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (44) (47) (44) (46)
Intestine Large (46) (48) (47) (46)
Intestine Small (44) (47) (47) (46)
Ileum, Sarcoma, Metastatic, Ovary 1 (2%)
Jejunum, Adenoma 1 (2%)
Liver (47) (48) (47) (47)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 1 (2%) 2 (4%)
Hepatocellular Adenoma 3 (6%) 6 (13%) 4 (9%) 8 (17%)
Hepatocellular Adenoma, Two 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Pancreas (45) (48) (47) (45)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Salivary Glands (47) (48) (47) (47)
Stomach (46) (48) (47) (46)
Forestomach, Mast Cell Tumor Malignant 1 (2%)
Forestomach, Squamous Cell Carcinoma 1 (2%)
Forestomach, Squamous Cell Papilloma 2 (4%) 1 (2%) 1 (2%)
Glandular, Sarcoma, Metastatic, Skin 1 (2%)
Glandular, Sarcoma, Metastatic, Skeletal
Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (47) (48) (47) (47)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Islets, Pancreatic (44) (48) (47) (45)
Adenoma 1 (2%)
Pituitary Gland (41) (45) (44) (46)
Pars Distalis, Adenoma 3 (7%) 1 (2%) 2 (4%)
Thyroid Gland (46) (48) (47) (47)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (46) (48) (47) (44)
Choriocarcinoma 1 (2%)
Cystadenocarcinoma 1 (2%)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Teratoma Benign 2 (4%)
Uterus (46) (48) (47) (46)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyoma 1 (2%) 1 (2%)
Sarcoma Stromal 2 (4%)
Vagina (45) (47) (47) (46)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (46) (48) (47) (46)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (47) (48) (47) (47)
Lumbar, Histiocytic Sarcoma 1 (2%)
Mandibular, Histiocytic Sarcoma 1 (2%)
Mandibular, Mast Cell Tumor Malignant 1 (2%)
Mesenteric, Histiocytic Sarcoma 1 (2%)
Mesenteric, Sarcoma, Metastatic, Skin 2 (4%)
Spleen (45) (48) (47) (45)
Hemangiosarcoma 2 (4%)
Thymus (43) (45) (45) (43)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (46) (48) (47) (45)
Adenoacanthoma 2 (4%) 1 (2%)
Carcinoma 1 (2%) 1 (2%) 1 (2%) 4 (9%)
Carcinoma, Two 1 (2%)
Skin (46) (48) (45) (45)
Fibrous Histiocytoma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Mast Cell Tumor Benign 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Sarcoma 1 (2%) 2 (4%)
Tail, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (47) (48) (47) (46)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (47) (48) (47) (47)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (47) (48) (47) (47)
Adenoacanthoma, Metastatic, Mammary Gland 2 (4%)
Alveolar/Bronchiolar Adenoma 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skin 2 (4%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Nose (47) (48) (47) (47)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (47) (48) (47) (47)
Adenocarcinoma 1 (2%) 1 (2%)
Adenoma 2 (4%) 2 (4%) 4 (9%) 4 (9%)
Bilateral, Adenoma 1 (2%)
Zymbal's Gland (47) (47) (46) (47)
Mast Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (47) (48) (47) (47)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Urinary Bladder (46) (48) (47) (44)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Page 5
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(47) *(48) *(47) *(47)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Lymphoma Malignant 6 (13%) 5 (10%) 12 (26%) 6 (13%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 93029-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC LEUKOMALACHITE GREEN Date: 06/19/03
Route: DOSED FEED Time: 07:04:42
____________________________________________________________________________________________________________________________________
C57BL/6N XC3H/HEN MTN-NCTR FEMALE 0 PPM 91 PPM 204 PPM 408 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 28 22 26 32
Total Primary Neoplasms 48 30 35 41
Total Animals with Benign Neoplasms 16 14 13 19
Total Benign Neoplasms 17 15 15 20
Total Animals with Malignant Neoplasms 16 11 18 17
Total Malignant Neoplasms 31 15 20 21
Total Animals with Metastatic Neoplasms 3 1 4
Total Metastatic Neoplasm 3 3 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------